SCHEMBL1715431

SCHEMBL1715431

CN1C(=O)NC(=O)C12CCc1cc(C(=O)O)ccc1C2

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 2/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
BLM P54132 1/20 0.43
GRM1 Q13255 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MEN1 O00255 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
CALCRL Q16602 13/20 0.41
KDM1A O60341 1/20 0.39
MAP2K2 P36507 3/20 0.39
ADM2 Q7Z4H4 1/20 0.39
RXRA P19793 1/20 0.39
TDP2 O95551 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12152864 0.90 CALCRL (0.43) MAPTCALCRLMAP2K2
SCHEMBL15401458 0.89 CALCRL (0.46) CALCRLMAP2K2ADM2
SCHEMBL12698621 0.89 CALCRL (0.46) CALCRLMAP2K2ADM2
SCHEMBL15400764 0.89 CALCRL (0.46) CALCRLMAP2K2ADM2
SCHEMBL12622663 0.86 CALCRL (0.41) CALCRLMAP2K2ADM2
SCHEMBL12655216 0.86 CALCRL (0.41) CALCRLMAP2K2ADM2
SCHEMBL1714985 0.81 BRD4 (0.42) CALCRLTDP2
SCHEMBL4958656 0.80 CALCRL (0.41) KDM4ETDP1KMT2ACALCRLMAP2K2
SCHEMBL13015183 0.78 CALCRL (0.39) CALCRLMAP2K2ADM2
SCHEMBL16626819 0.75 CALCRL (0.47) CALCRLMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1912653-B1 HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2014-01-01 EP disclosed
EP-2091533-B1 CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-11-28 EP disclosed
WO-2011070283-A8 METHOD AND APPARATUS FOR COOLING AND/OR DEEP-FREEZING MATERIALS IMPLEMENTING THE INJECTION OF TWO CRYOGENIC LIQUIDS L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude (FR) 2012-05-10 WO disclosed
EP-1606264-B1 MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-05-02 EP disclosed
EP-1606264-B1 MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-05-02 EP disclosed
US-8071770-B2 Spirohydantoin aryl CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-12-06 US disclosed
US-8071770-B2 Spirohydantoin aryl CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-12-06 US disclosed
US-8071770-B2 Spirohydantoin aryl CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-12-06 US disclosed
US-8071771-B2 Bicyclic spirohydantoin CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-12-06 US disclosed
US-8071771-B2 Bicyclic spirohydantoin CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-12-06 US disclosed
US-7192954-B2 Monocyclic anilide spirohydantoin CGRP receptor antagonists MERCK & CO., INC. (US) 2007-03-20 US disclosed
US-7192954-B2 Monocyclic anilide spirohydantoin CGRP receptor antagonists MERCK & CO., INC. (US) 2007-03-20 US disclosed
US-7189722-B2 Aryl spirohydantoin CGRP receptor antagonists MERCK & CO., INC. (US) 2007-03-13 US disclosed
US-7189722-B2 Aryl spirohydantoin CGRP receptor antagonists MERCK & CO., INC. (US) 2007-03-13 US disclosed
US-7189722-B2 Aryl spirohydantoin CGRP receptor antagonists MERCK & CO., INC. (US) 2007-03-13 US disclosed
WO-2007016087-A2 HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-02-08 WO disclosed
US-20060211712-A1 Bicyclic anilide spirohydantoin cgrp receptor antagonists MERCK SHARP & DOHME LLC 2006-09-21 US disclosed
US-20060189593-A1 Aryl spirohydantoin cgrp receptor antagonists MERCK SHARP & DOHME LLC 2006-08-24 US disclosed
US-20060189600-A1 Benodiazepine spirohydantoin cgrp receptor antagonists MERCK SHARP & DOHME LLC 2006-08-24 US disclosed
US-20060148779-A1 Monocyclic anilide spirohydantoin cgrp receptor antagonists MERCK SHARP & DOHME LLC 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189600-A1 Benodiazepine spirohydantoin cgrp receptor antagonists BDKRB2, BDKRB1, CNR2 ALDH1A1 1317/4885KDM4E 3938/4885MAPT 2874/4885
US-20060148779-A1 Monocyclic anilide spirohydantoin cgrp receptor antagonists CALCRL, CALCR, CCKAR ALDH1A1 1423/4885KDM4E 3616/4885MAPT 2482/4885
US-20060211712-A1 Bicyclic anilide spirohydantoin cgrp receptor antagonists BDKRB2, CALCRL, CCKBR ALDH1A1 1107/4885KDM4E 4090/4885MAPT 2811/4885
US-20060189593-A1 Aryl spirohydantoin cgrp receptor antagonists CALCRL, BDKRB2, MRGPRX1 ALDH1A1 1249/4885KDM4E 3832/4885MAPT 3523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.